Andere Sprachen Mydecine Innovations Group Inc.

Aktien

A3DKEJ

CA62849F2008

MYCOF

Markt geschlossen - OTC Markets Andere Börsenplätze 19:36:59 29.04.2024			% 5 Tage	% 1. Jan.
0.0147 ^USD	-33.45%		+32.43%	-1.34%

23.02.	Mydecine Innovations schließt teilweisen Schuldenvergleich ab	MT
02.02.	Mydecine Innovations Group Inc. gibt den Rücktritt von Neil Stevenson-Moore als Direktor bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Mydecine Announces Intention to Refile Certain Financial Statements and Applies for Management Cease Trade Order	26.04.
Mydecine Innovations Group Inc. Announces Share for Debt Settlement	20.03.
Mydecine Innovations Closes Partial Debt Settlement	23.02.
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds	07.02.
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds	07.02.
Mydecine Innovations Group Announces Director Resignation	02.02.
Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director	02.02.
Mydecine Innovations Group Receives Notice of Allowance from USPTO For MYCO-005 Compound	18.12.
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound	18.12.
Mydecine Announces Update Regarding the Special Access Program	28.11.
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18.11.
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements	31.10.23
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements	31.10.23
Mydecine Innovations Group Provided Q4 2023 Business Update	26.10.23
Mydecine Provides Q4 2023 Business Update	26.10.23
Mydecine Provides Q4 2023 Business Update	26.10.23
Mydecine Innovations Group gearing up for human trials after completing Aquis listing	18.10.23
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK	12.10.23
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK	12.10.23
Mydecine Innovations Group Brief: Announced Admission to Trading on AQSE Growth Market in London, UK and First Day of Dealings	10.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mydecine Innovations Group Inc.

Aktien

A3DKEJ

CA62849F2008

MYCOF

Andere Sprachen

Filter